Product Images Lenalidomide

This text contains information about Lenalidomide capsules with a warning about potential human birth defects. Each capsule contains 10 mg of Lenalidomide, and the usual dosage should be determined based on prescribing information. The medication should be stored at 20°C to 25°C with excursions permitted to 15°C to 30°C. The package is child-resistant and should be kept out of reach of children. The manufacturer is Biocon Pharma Limited in India, and the medication guide should be dispensed to each patient.*

This is a description of Lenalidomide capsules containing 15 mg each, with a warning about the potential for human birth defects. It includes information about the usual dosage, storage instructions, child-resistant packaging, manufacturer details, and a reference to the enclosed Medication Guide. The medication is advised to be kept out of reach of children.*

This text contains information about Lenalidomide capsules, with each capsule containing 25 mg of Lenalidomide. It advises dispensing the medication guide to each patient and highlights the warning about the potential for human birth defects. The usual dosage is to be determined as per prescribing information. The manufacturer is Biocon Pharma Inc., from Iselin, NJ, USA, and the manufacturing site is Biocon Pharma Limited in Bengaluru, India. The storage conditions, dosage, and administration details are provided, along with a reminder to keep all drugs out of the reach of children and that the packaging is child-resistant.*

This text contains information about Lenalidomide capsules, warning about the potential for human birth defects. Each capsule contains 2.5 mg of Lenalidomide. The medication guide should be dispensed to each patient. The usual dosage should be determined according to prescribing information. The medication should be stored at temperatures between 20°-25°C (68-77°F). The packaging is child-resistant and manufactured by Biocon Pharma in the USA and India. It is essential to keep all drugs out of the reach of children.*

This is a table presenting survival probabilities (%) and progression-free survival data over various time points for different treatment groups (Rd Continuous, Rd18, and MPT). The table also includes hazard ratios, confidence intervals, and p-values for the comparisons between the treatment groups. The data provides insights into the effectiveness of different treatments in terms of survival and progression-free survival rates.*

The provided text contains a survival probability chart comparing Rd Continuous, Rd18, and MPT treatments over time. It includes overall survival months and survival probabilities for different time points. The text also mentions the number of subjects at risk for each treatment group.*

The text provides data comparing Lenalidomide to Placebo in a study. The hazard ratio (HR) and confidence intervals (95% CI) for progression-free survival (PFS) are mentioned. The median Kaplan-Meier survival times are provided for both groups. The number of subjects at risk and the percentage of PFS events are also presented for each group.*

This is a statistical report showing the progression-free survival in months for a placebo group compared to a treatment group using Lenalidomide. The data presents the number of subjects at risk for each group as well.*

This information shows the proportion of subjects at various time points in a study comparing lenalidomide/Dex versus Placebo/Dex. The data presents the percentage of subjects at 100%, 75%, and 50% levels. The study also indicates that the relative risk (R) is 0.285 with a confidence interval (95% CI) of 0.210-0.386, and the Log Rank test showed a significant result with p < 0.001. Time to Progression in months is also displayed.*

This text provides statistical data on the proportion of subjects at different time intervals in a study comparing placebo/Dex and lenalidomide/Dex. The relative risk (R) and its confidence interval (CI) are given as well as the log-rank p-value. The comparison is based on the time to disease progression in months.*

This text appears to display data related to survival probability and progression-free survival with different treatments. It compares the outcomes between two treatment groups involving Rtwimeb + Lendolimide and Rituimeb + Placebo. The Hazard Ratio (HR) is reported along with confidence intervals, suggesting a significantly different effect between the two treatments. The numbers under "Progression-free Survival (Months)" denote the number of subjects at risk at various time points. Further analysis can provide insights into the effectiveness of these treatments in relation to survival rates and disease progression.*